HC Wainwright Has Weak Outlook for Invivyd FY2028 Earnings

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Stock analysts at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for Invivyd in a research note issued to investors on Monday, August 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.13 per share for the year, down from their prior estimate of $0.18. HC Wainwright currently has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Invivyd's current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd's FY2029 earnings at $0.22 EPS.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%.The company had revenue of $11.79 million during the quarter, compared to the consensus estimate of $23.16 million.

Separately, D. Boral Capital lowered their price objective on shares of Invivyd from $9.00 to $3.00 and set a "buy" rating for the company in a research note on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $3.85.

Invivyd Trading Down 16.7%

Shares of Invivyd stock traded down $0.1059 on Tuesday, hitting $0.5279. 4,177,051 shares of the company traded hands, compared to its average volume of 930,519. The company has a market cap of $63.42 million, a PE ratio of -0.57 and a beta of 0.51. The stock's 50 day moving average price is $0.74 and its 200-day moving average price is $0.83. Invivyd has a 52 week low of $0.3546 and a 52 week high of $2.74.

Insider Transactions at Invivyd

In other news, insider Jill Andersen sold 49,402 shares of the firm's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total value of $28,159.14. Following the sale, the insider directly owned 84,446 shares in the company, valued at approximately $48,134.22. This trade represents a 36.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 277,654 shares of company stock valued at $167,215 in the last 90 days. 25.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Invivyd

Hedge funds have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd acquired a new position in shares of Invivyd in the 2nd quarter valued at $27,000. Vanguard Personalized Indexing Management LLC grew its stake in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after purchasing an additional 28,146 shares during the last quarter. Nuveen LLC acquired a new position in shares of Invivyd in the first quarter valued at about $65,000. Invesco Ltd. raised its stake in shares of Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company's stock worth $66,000 after purchasing an additional 71,485 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Invivyd during the first quarter worth about $66,000. Institutional investors and hedge funds own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.